Skip to main
BDTX
BDTX logo

BDTX Stock Forecast & Price Target

BDTX Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Black Diamond Therapeutics Inc is positioned favorably in the oncology market with its unique MasterKey therapies targeting families of oncogenic mutations, including drugs such as BDTX-4933 and BDTX-1535, which are designed to improve patient outcomes. The company's upcoming catalysts, particularly in the assessment of acute loss of treatment durability measures and overall response rates, are anticipated to significantly increase projected sales to between $500 million and $750 million by 2026, suggesting substantial revenue potential. Additionally, Black Diamond's demonstrated efficacy, especially with the silevertinib drug, highlights a promising viability in key treatment areas, which could command a considerable market share, enhancing the company's financial outlook and growth prospects.

Bears say

The analysis indicates concerns regarding the replicability of reported efficacy results for Black Diamond Therapeutics' drug silevertinib, as a lower dosage raises doubts about its overall effectiveness, reflected by a correlation with significantly adjusted probabilities of success. Comparatively, its clinical response rate (cORR) in certain subsets is underwhelming when measured against competitors, notably fimoterinib, which may undermine silevertinib's market potential. Additionally, the company's current market capitalization of approximately $230 million suggests investor skepticism surrounding silevertinib's competitiveness in the 1L EGFR-NCM patient population, particularly if future trials reveal less favorable outcomes.

BDTX has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Black Diamond Therapeutics (BDTX) Forecast

Analysts have given BDTX a Strong Buy based on their latest research and market trends.

According to 5 analysts, BDTX has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Black Diamond Therapeutics (BDTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.